Open Study of Phase I / II Evaluating Tolerance and Efficacy of Mobilization and Collection of Peripheral Hematopoietic Stem Cells Device After a Single Injection of 0.24mg/kg of Plerixafor in Sickle Cell Patients
Phase of Trial: Phase I/II
Latest Information Update: 27 Dec 2017
Price : $35 *
At a glance
- Drugs Plerixafor (Primary)
- Indications Stem cell mobilisation
- Focus Adverse reactions
- Acronyms DrepaMob
- 31 Aug 2018 Biomarkers information updated
- 20 Dec 2017 Status changed from recruiting to completed.
- 25 Aug 2016 Status changed from not yet recruiting to recruiting.